The text starts here.

News Release

FOR IMMEDIATE RELEASE
May 18, 2017

EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 53RD ASCO ANNUAL MEETING
RESULTS OF STUDY OF LENVIMA® (LENVATINIB) IN HEPATOCELLULAR CARCINOMA TO BE PRESENTED IN ORAL SESSION

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate (selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, product name: Lenvima® / Kisplyx®, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven®, “eribulin”), as well as H3B-8800, a splicing modulator discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 2 to 6, 2017.

Detailed data regarding the results of a Phase III clinical trial (Study 304) of lenvatinib compared with sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma, which has already achieved its primary endpoint, will be presented orally at the ASCO Annual Meeting. This presentation is scheduled to take place on Sunday, June 4, 8:12 AM local time, in Hall D2.

Major poster presentations will include a highlight of the results of a Phase Ib/II clinical trial (Study 111) of lenvatinib in combination with the anti-PD-1 antibody pembrolizumab for the treatment of patients with endometrial carcinoma, and the results of a Phase I clinical trial of H3B-8800 in patients with advanced myeloid malignancies.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

Oral Presentations:
ProductAbstract title and scheduled presentation date and time (local time)
Lenvatinib

Abstract No: 4001
Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Oral Presentation | June 4 (Sun), 8:12-8:24 AM
Major Poster Presentations:
ProductAbstract title and scheduled presentation date and time (local time)
Lenvatinib

Abstract No: 5598
A Phase Ib/II Trial of Lenvatinib (LEN) Plus Pembrolizumab (Pembro) in Patients (Pts) With Endometrial Carcinoma
Poster Presentation | June 3 (Sat), 1:15-4:45 PM
Lenvatinib


Abstract No: TPS4595
A Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab vs Sunitinib Alone in First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Poster Presentation | June 4 (Sun), 8:00-11:30 AM
Lenvatinib

Abstract No: 10544
Single-agent Dose-finding Cohort of a Phase 1/2 Study of Lenvatinib (LEN) in Children and Adolescents with Refractory or Relapsed Solid Tumors
Poster Presentation | June 4 (Sun), 8:00-11:30 AM
Eribulin

Abstract No: 6603
Validity and Reliability of Four Value Frameworks for Cancer Drugs

Poster Presentation | June 5 (Mon), 1:15-4:45 PM
H3B-8800

Abstract No: TPS7075
H3B-8800-G0001-101: A first in human phase I study of a splicing modulator in patients with advanced myeloid malignancies
Poster Presentation | June 5 (Mon), 8:00-11:30 AM

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120